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Background: Background rates of latent tuberculosis infection in low prevalence regions of Britain are unknown.
These would be valuable data for interpreting positive IGRA results, and guiding cost-benefit analyses. The
management of a large outbreak of tuberculosis occurring in a rural district hospital provided an opportunity to
determine the background rates and epidemiology of IGRA-positivity amongst unselected hospital patients in a
low-prevalence region of U.K.
Methods: As part of a public health surveillance project we identified 445 individuals exposed to the index cases
for clinical assessment and testing by a TB-specific interferon-γ release assay (IGRA): T-Spot.TB. Uniquely, an
additional comparator group of 191 age-matched individuals without specific recent exposure, but with a similar
age distribution and demographic, were recruited from the same wards where exposure had previously occurred,
to undergo assessment by questionnaire and IGRA.
Results: Rates of IGRA positivity were 8.7% (95%CI, 4.2-13, n=149) amongst unexposed patients, 9.5%(3.0-22, n=21)
amongst unexposed staff, 22%(14–29, n=130) amongst exposed patients, 11%(6.1-16, n=142) amongst exposed
staff. Amongst the individuals without history of recent exposure to the outbreak, IGRA-positivity was associated
with prior TB treatment (OR11, P.04) and corticosteroid use (OR5.9, P.02). Background age-specific prevalences of
IGRA-positivity amongst unexposed individuals were: age <40 0%(N/A), age 40–59 15%(12–29), age 60–79 7.0%(1.1-
13), age≥80 10%(5.9-19).
Conclusions: Background rates of IGRA-positivity remain high amongst unselected white-Caucasian hospital
inpatients in U.K. These data will aid interpretation of future outbreak studies. As rates peak in the 5th and 6th
decade, given an ageing population and increasing iatrogenic immunosuppression, reactivation of LTBI may be a
persistent hazard in this population for several decades to come.
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Background rates of latent tuberculosis infection (LTBI)
in low prevalence regions of Britain are unknown.
Current estimates depend on extrapolations from the in-
cidence of active cases of TB [1], or on tuberculin skin
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reproduction in any medium, provided the orspecific interferon-γ release assays (IGRAs) are sensitive
and specific methods for detecting immune sensitisation
by TB [3], and have accurately characterised the epi-
demiology of LTBI amongst high risk populations such
as recent immigrants or TB contacts. The few studies
which have reported on IGRA-positivity in healthcare
workers place rates in the range of 6.7-9.9% in low
prevalence countries [4]. However there is a paucity of
data on the background rates of IGRA-positivity in low
risk populations, such as hospital in patients without re-
cent TB exposure [1]. Such data would be valuable fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IGRA result in low risk populations, and further inform-
ing cost-benefit analyses of new diagnostics [1].
We undertook to manage an outbreak in a low preva-
lence region by contact tracing with standard IGRA
testing according to the “stone in the pond” principle
[1], and also to determine the background rates and
epidemiology of IGRA-positivity amongst unselected,
unexposed hospital patients in a low-prevalence region
of U.K.
Methods
In June 2009 a patient was diagnosed with smear-
positive pulmonary tuberculosis over three weeks after
admission to Salisbury District Hospital, a rural district
general hospital in South West England. Over the subse-
quent 15 months a further 8 secondary cases of active
TB were diagnosed amongst staff and patients. 6/6
culture-confirmed cases had identical VNTR (variable
number tandem repeat) profile, so were directly attribut-
able to the index case, given the very low incidence of
active TB locally at 6.1/100,000/year [5]. Contact tracing
identified 445 potential contacts of the index case,Table 1 Demographics and T-Spot results of all participants
Exposed
Staff Patients
n=142 n=134
n % (95% CI) n %
Age (years), median (range) 34 (18 to 69) 73 (27 to 9
Male, n (%)† 25 (17) 60 (45)
Ethnicity, n (%)
White Caucasian - - 133 (99)
Hispanic - - 1 (0.7)
Asian‡ - - 0 (0)
BCG (history or scar), n (%)
Yes 119 (84) 55 (41)
No 8 (5.6) 57 (43)
Unknown 1 (0.7) 22 (16)
TSpot result including initial borderline results, n, (%) (95%CI)
Positive 14 (9.9) (5.0 to 15) 28 (21)
Borderline positive 2§ (1.4) (0 to 3.3) 3 (2.2)
Borderline negative 6§ (4.2) (0.92 to 7.5) 1 (0.7)
Negative 120 (85) (79 to 90) 102 (76)
TSpot result excluding those borderline results which were not retested, n, (%
(95%CI)
Positive 16 (11) (6.1 to 16) 28 (22)
Negative 126 (89) (84 to 94) 102 (78)
† Percentages are those of those with valid data (e.g. occupation).
‡ India (1), Philippines (1).
§ Borderline results were retested and definitive results reached in every case. 2 (of
6 (of which one was borderline negative) became negative (reversions).comprising 142 staff and 303 patients. These two groups
of “exposed staff” and “exposed patients” were defined
by having received treatment or worked regularly on the
same wards at the same time that the index case was
present, and were therefore considered to have had
known, recent exposure to MTB. “Exposed staff” had a
median age of 34 (range 18 to 69) and 84% were BCG
vaccinated. “Exposed patients” were older with a median
age of 73 (range 27 to 95) and only 41% were known to
be BCG vaccinated. See Table 1 and Figure 1.
Uniquely, to inform interpretation of positive results
obtained amongst the exposed contacts, two additional
comparator groups of “unexposed” individuals were
recruited. These comprised a further 191 individuals
with a similar age distribution recruited from staff (“un-
exposed staff”, n=22) and adult patients (“unexposed
patients”, n=169), see Figure 1. These individuals were
recruited from the same respiratory and general medical
wards where exposure had previously occurred, but who
had not been exposed to any of the 9 cases at the time
of their admissions. Subjects with any suspected TB ex-
posure within the last 2 years were excluded. Demo-
graphics of the unexposed individuals are shown inUnexposed
Staff Patients
n=22 n=156
(95% CI) n % (95% CI) n % (95% CI)
5) 44 (23 to 60) 71 (25 to 93)
7 (32) 77 (49)
20 (91) 156 (100)
0 (0) 0 (0)
2 (9) 0 (0)
18 (82) 75 (48)
3 (14) 50 (32)
1 (5) 30 (19)
(14 to 27) 2 (9.1) (0 to 21) 13 (8.3) (4.0 to 13)
(0 to 4.7) 0 (0) (N/A) 5 (3.2) (0.44 to 6.0)
(0 to 2.2) 1 (4.5) (0 to 13) 2 (1.3) (0 to 3.0)
(68 to 82) 19 (86) (72 to 100) 136 (87) (82 to 92)
)
(14 to 29) 2 (9.5) (0 to 22) 13 (8.7) (4.2 to 13)
(71 to 85) 19 (90) (78 to 100) 136 (91) (87 to 96)
which one was borderline negative) became positive (conversions),
142 Staff
445 Exposed contacts
303 Patients
66 Died to 
Prior to testing
237 Full clinical
data available
102 Blood
not taken
1 Indeterminate
assay
28
Positive
102
Negative
4*
Borderline
135 
TSpot assay 
performed
142 Full clinical
data available
16
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142 
TSpot assay 
performed
22 Staff
191 Unexposed controls
169 Patients
169 Full clinical
data available
3 Blood
not taken
10 Indeterminate
assays
13
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136
Negative
7‡
Borderline
166 
TSpot assay 
performed
22 Full clinical
data available
2
positive
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22 
TSpot assay 
performed
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Figure 1 Study flow chart showing all participant cohorts. * comprises 3 borderline positive, 1 borderline negative; † comprises 1 borderline
negative; ‡ comprises 5 borderline positive, 2 borderline negative.
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(range 23 to 95) and 82% were BCG vaccinated. “Unex-
posed patients” were older with a median age of 71
(range 25 to 93) and only 48% were known to be BCG
vaccinated. This sample size was predicted to give a con-
fidence interval width for overall LTBI prevalence of
<4.5%.
Participants were invited for screening by history and
IGRA. Samples were couriered to Oxford Immunotec
for testing by T-Spot.WTB. (Oxford Immunotec, Oxford,
U.K.) A positive result comprised ≥8 spot-forming col-
onies (SFC) more than the control well. A result of 5, 6
or 7 SFC was considered borderline and the subject
retested where possible, or removed from subsequent
analysis. 95% confidence intervals and multivariate bin-
ary logistic regression (at P<0.05), were calculated using
SPSS version 19.0 (IBM Corp., Armonk, NY).
Subjects provided written consent. As a primarily pub-
lic health surveillance exercise the National Research
Ethics Service advised this study did not require review
by a NHS Research Ethics Committee.Results
Full clinical data were available and IGRA performed on
465 staff and patients. Study design and assay results are
shown Figure 1. Demographic data for the complete in-
vestigation are presented in Table 1. All 142 exposed
staff completed screening. Amongst the group of
exposed patients, testing was not performed in 168
exposed patients because they had died (n=66), or
(n=102) testing was declined due to patient preference
or considered inappropriate, for example due to instiga-
tion of end of life care. Three unexposed patients with-
drew consent. Overall 11 assays were indeterminate
because of insufficient cells (n=9) – predominantly due
to under-filled tubes – or high background (n=2).
The rates of IGRA positivity were: unexposed patients
8.7%(95%CI, 4.2-13, n=13/149), unexposed staff 9.5%
(95%CI, 3.0-22, 2/21), exposed patients 22%(95%CI, 14–
29, 28/130), exposed staff 11%(95%CI, 6.1-16, 16/142).
From these data we estimate an additional 35/379 liv-
ing staff (n=142) and patients (n=237) known to be
exposed during this outbreak, would test positive by
Table 2 Demographics of the unexposed individuals
Unexposed, age-matched individuals
TSpot positive n=13 TSpot negative n=136 Odds ratio Univariate P
n % n %
Age (years), median (range) 64 (45-87) 70 (25-93) 0.81
Male, n (%) 5 (38) 70 (52) 0.36
Ethnicity, n (%)
White Caucasian 13 (100) 136 (100)
Country of birth
UK born 9 (69) 126 (93) 0.18 0.006
Other 4 (31)† 10 (7.4)
Years since immigration, median (range) 43 (21-62) 52 (8-61)
Ever visited a high prevalence country, n (%) 4 (31) 47 (35) 0.84
Years since last visit, median (range) 8.5 (0-40) 5.5 (0-60)
Ever resident in a high prevalence area >6/52, n (%) 2 (15) 27 (20) 0.64
Occupation: healthcare, prison, lab n (%)‡ 4 (31) 18 (13) 0.09
BCG (history or scar), n (%)
Yes 7 (54) 66 (49) 0.73
No 4 (31) 44 (33)
Unknown 2 (15) 26 (19)
Medical history, n (%)
Comorbidity known to be associated with TB§ 0 (0) 21 (16) 0.22
Immunosuppresive medications∥ 4 (31) 12 (9.2) 4.6 0.015
Ever known to be exposed to TB 4 (31) 26 (19) 0.32
Ever had treatment for tuberculosis 2 (15) 2 (1.5) 12 0.003
† Germany (2), South Africa (1), Hong Kong (1).
‡ Percentages are those of those with valid data.
§ Diabetes mellitus (17), chronic renal failure (3), haematological malignancy (2), gastric surgery (1).
∥ Systemic steroids (12), methotrexate (4), hydroxychloroquine (2), anti-TNF alpha (2), sulfasalzine (1).
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IGRAs probably reflect recently-acquired LTBI.
Amongst unexposed patients positive IGRA results
were positively associated in multivariate analyses with
history of previous TB treatment (OR 11, P=.04) and
with use of corticosteroids (OR 5.9, P=.02). 6/13 IGRA-
positive unexposed patients had a history of TB
treatment (n=2), definite (n=2) or probable (n=2) TB
exposure. Age-specific prevalences of IGRA-positivity
amongst all unexposed patients were: age <40 0%(95%CI
N/A), age 40–59 15%(95%CI 12–29), age 60–79 7.0%
(95%CI 1.1-13), age≥80 10%(95%CI 5.9-19) (Figure 2a,b).Discussion
We observed a background rate (8.7%) of IGRA-
positivity amongst an unselected population typical of
respiratory and general medical inpatients in a rural dis-
trict hospital in U.K. All these “unexposed” patients,
without known recent TB exposure, were white-Cauca-
sians, a population in whom data on LTBI prevalenceare lacking [2], but who comprise 92% of the U.K. popu-
lation [6]. As the South West region has the lowest inci-
dence of active tuberculosis in mainland Britain [5], and
as our findings accord with a 9.0% rate in a similar study
using QuantiFERONW-TB in Northern Ireland [7], this
may represent a current minimum U.K. background rate
of IGRA-positivity.
Rates of IGRA-positivity amongst unexposed control
patients were higher in subjects receiving long term iat-
rogenic immunosuppression (OR 5.9). This would be
consistent with the known increased risk of acquiring
MTB-complex infection due to impairment of cell-
mediated immunity induced by therapy with corticoster-
oids or with anti-TNFα therapy [8].
The 9.5% rate of IGRA-positivity amongst the unex-
posed staff is consistent with a rate of 9.9% observed by
Schablon et al. in their large study of healthcare workers
in Germany [4]. These authors observed associations be-
tween IGRA positivity and older age, foreign birth and
prior personal history of TB. In our study the IGRA
positive, unexposed staff were neither foreign born nor
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Figure 2 Age specific prevalences of IGRA-positivity amongst
exposed patients and amongst unexposed patients. Error bars
show standard errors of the mean. a) data stratified according to
four age-groups. b) data stratified by seven age groups, as per
Syed et al. [2].
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decade. It seems likely that relatively high rates of
IGRA-positivity in healthcare workers may be due to un-
recognised occupational exposure to MTB, particularly
in older workers whose exposure may predate current
infection control procedures.
Interestingly the age-specific prevalence amongst un-
exposed controls shows a similar bimodal distribution to
that observed in the early 1990s in Liverpool [2] using
the Heaf method. The lower absolute values reflect the
greater specificity of T-Spot.TB and the declining rates
of TB amongst U.K. born individuals [9-11]. It is esti-
mated that the annual risk of infection in U.K. declined
from 12% in 1901 to 1.9% in 1949 [10] and has since
fallen further [11]. Nonetheless our data suggest there isstill a peak in the 5th and 6th decades, as observed two
decades ago [2].
Do these positive IGRAs represent true LTBI? A posi-
tive T-Spot.TB assay is evidence of previous immune
sensitisation by specific antigens from M.tb complex
[3,12]. 6/13 IGRA-positive individuals without recent ex-
posure had a known history of prior TB infection or ex-
posure. That T-Spot responses wane over time [13], or
may be transiently positive [3], suggests some individuals
might spontaneously clear M.tb infection. Alternatively,
as early secretory antigenic target 6 and culture filtrate
protein 10 are expressed by other opportunistic myco-
bacteria [14], and indeed QuantiFERON responses have
been observed with M.marinum, M.kansasii, and M.
szulgai [12] some positive IGRA results might be attrib-
utable to other opportunistic mycobacteria, or even to
unpasteurised dairy products [7], or the M.bovis epi-
demic affecting more than 5% of cattle herds locally
[15], although we found no association with farming oc-
cupation (Data not shown).
This study has several potential limitations: sample
sizes are relatively small, particularly amongst younger
age-groups; data may not be directly generalizable to
other regions or non-hospital communities; due to the
time-course of the outbreak, sample sizes and use of
chemoprophylaxis, the study was not designed to pro-
vide data on rates of progression amongst IGRA positive
individuals.Conclusions
8.7% of unselected white-Caucasian medical inpatients
in a low-prevalence region test positive by T-Spot. As
this region has the lowest UK incidence of active TB,
this figure may represent a current minimum UK back-
ground prevalence of LTBI. These data will aid interpret-
ation of future outbreak studies. They will also inform
cost-benefit analyses which may be sensitive to assumed
background rates of LTBI. As rates peak in the 5th and
6th decade, given an ageing population and increasing
iatrogenic immunosuppression, reactivation of LTBI may
be a persistent hazard in this population for several dec-
ades to come.
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